Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Status:
Terminated
Trial end date:
2017-04-08
Target enrollment:
Participant gender:
Summary
Plerixafor in combination with bevacizumab is a drug combination that may stop cancer cells
from growing abnormally. Bevacizumab, also known as Avastin, is FDA approved for use in
patients with recurrent glioblastoma and has been studied extensively in other types of solid
tumors. Plerixafor, also known as Mozobil, is FDA approved for use in patients with
non-Hodgkin's lymphoma and multiple myeloma and has been used in treatment for other cancers.
Information from experiments in laboratories suggests that the combination of plerixafor and
bevacizumab may help prevent the growth of gliomas.
Part 1: The investigators are looking for the highest dose of plerixafor that can be given
safely with bevacizumab (with a 21 days on/7 days off regimen of plerixafor). The
investigators will also do blood tests to find out how the body uses and breaks down the drug
combination.
Part 2: The investigators are looking to see if plerixafor can get past the blood-brain
barrier and into brain tumors. The investigators will also do blood tests to find out how the
body uses and breaks down the drug combination.
Part 3: The investigators are looking for for more information re: safety and tolerability of
plerixafor in combination with bevacizumab (with a 28 days on/0 days off regimen of
plerixafor). The investigators will also do blood tests to find out how the body uses and
breaks down the drug combination.
Phase:
Phase 1
Details
Lead Sponsor:
Patrick Y. Wen, MD
Collaborators:
Brigham and Women's Hospital Dana-Farber Cancer Institute Genzyme, a Sanofi Company Massachusetts General Hospital